cyclophosphamide + methotrexate + fluorouracil + vincristine + prednisone + vinblastine + doxorubicin + thiotepa + fluoxymesterone

This is a multi-agent chemotherapy combination consisting of nine drugs: cyclophosphamide, methotrexate, fluorouracil (5-FU), vincristine, prednisone, vinblastine, doxorubicin (also known as Adriamycin), thiotepa, and fluoxymesterone. Each component has a distinct mechanism of action targeting cancer cells through different pathways: - Cyclophosphamide is an alkylating agent that crosslinks DNA strands to inhibit cell replication. - Methotrexate is an antimetabolite that inhibits dihydrofolate reductase and disrupts DNA synthesis. - Fluorouracil (5-FU) is a pyrimidine analog that interferes with DNA and RNA synthesis by inhibiting thymidylate synthase. - Vincristine and vinblastine are vinca alkaloids that inhibit microtubule formation during mitosis. - Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties; it can induce apoptosis in certain cancer cells. - Doxorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II activity leading to double-strand breaks. - Thiotepa is an alkylating agent causing crosslinking of DNA strands. - Fluoxymesterone is an androgenic steroid sometimes used for its palliative effects in certain cancers. This combination would be considered highly intensive polychemotherapy. While several subsets of these drugs are used together in established regimens for breast cancer or lymphoma (such as CMF or CHOP), this exact nine-drug combination does not correspond to any standard named regimen but represents a broad-spectrum cytotoxic approach likely intended for aggressive malignancies.